Drug interactions with a focus on selected drug groups in cardiology


Authors: Juřica J.
Authors‘ workplace: Farmakologický ústav, LF MU, Ústav humánní farmakologie a toxikologie, FarmF MU, Ústavní lékárna, Masarykův onkologický ústav
Published in: Kardiol Rev Int Med 2020, 22(3): 97-102

Overview

The risk of drug interactions increases with the number of drugs used. The numbers vary between studies, however, according to one study, the risk of drug interaction with concomitant use of up to five drugs is only 4%, rising to 10% with 5–10 different drugs, over 28% in the group using 11–15 drugs and up to 54% when taking 16–20 different drugs. There are many reasons and possible explanations and each system has its own specifics. The aim of this article is to summarize the basic types of interactions and to give examples of drug interactions in cardiology.

Keywords:

Anticoagulants – proton pump inhibitors – Drug interactions – Diuretics – hypolipidemics – cardiology – antihypertensives – antiarrhythmics – antiagregation


Sources

1. Smith CM. Origin and uses of primum non nocere – above all, do no harm! J Clin Pharmacol 2005; 45 (4): 371–377. doi: 10.1177/0091270004273680.

2. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22 (3): 322–328. doi: 10.1002/cpt1977223322.

3. Egan LJ. Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid. Clin Gastroenterol Hepatol 2004; 2 (9): 725–730. doi: 10.1016/s1542-3565 (04) 00343-x.

4. Doligalski CT, Tong Logan A, Silverman A. Drug interactions: a primer for the gastroenterologist. Gastroenterol Hepatol (N Y) 2012; 8 (6): 376–383.

5. Michalets E. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18 (1): 84–112.

6. DynaMed. Ipswich (MA): EBSCO Information Services. 1995–2018; 2019. Available at: https: //connect.ebsco.com/s/article/How-to-Cite-Information-from-DynaMed?language=en_US.

7. Ritter J, Flower R, Henderson G et al. (eds.) Rang & Dale‘s Pharmacology (8th ed.). Edinburgh, New York Elsevier: Churchill Livingstone 2015.

8. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobio­tics. Cell Mol Life Sci 2001; 58 (5–6): 737–747. doi: 10.1007/pl00000897.

9. Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the „rank order“ approach. Drug Metab Lett 2007; 1 (1): 31–35. doi: 10.2174/187231207779814247.

10. FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 2020. Available at: https: //www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.

11. InfoPharm. AISLP. 2019. Dostupné na: https: //www.aislp.cz.

12. Flockhart D. Cytochrome P450 drug-interaction table. 2020. Available at: https: //drug-interactions.medicine.iu.edu/MainTable.aspx.

13. Franco D, Henao Y, Monsalve M et al. Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review. Farm Hosp 2013; 37 (6): 539–557. doi: 10.7399/FH.2013.37.6.1077.

14. Drug Interaction Checker. Available at: https: //reference.medscape.com/drug-interactionchecker.

15. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24 (2): 285–290. doi: 10.1592/phco.24.2.285.33137.

16. Engell AE, Svendsen AL, Lind BS et al. Drug-drug interaction between warfarin and statins: A Danish cohort study. Br J Clin Pharmacol 2020. doi: 10.1111/bcp.14428.

17. Kallergis EM, Goudis CA, Simantirakis EN et al. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal 2012; 2012: 212178. doi: 10.1100/2012/212178.

18. Woosley RL, Heise CW, Gallo T et al. QTdrugs List, 2020. AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 8575519.

19. Suchý D, Poklopová Z. Lékové interakce warfarinu s kardiovaskulárními léky. Klinická farmakologie a farmacie 2005; 19 (1): 40–42.

20. Doseděl M, Malý J, Vlček J. Lékové interakce statinů, jejich klinická závažnost a management. Remedia 2011; 21: 392–397.

21. Prokeš M, Suchopár J. Lékové interakce warfarinu a nových, přímých orálních antikoagulancií. Medicína pro praxi 2018; 15 (5): 267–275.

22. Wiggins BS, Dixon DL, Neyens RR et al. select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol 2020; 75 (11): 1341–1350. doi: 10.1016/j.jacc.2019.12.068.

23. Wurtz M, Grove EL, Kristensen SD et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96 (5): 368–371. doi: 10.1136/hrt.2009.181107.

24. Bultas J. Antiplatelet therapy – a pharmacolo­gist’s perspective. Cor Vasa 2013; 55: e86–e94.

25. Bultas J, Karetová D. Rutinní kombinace duální protidestičkové léčby s inhibitory protonové pumpy – nevyléváme vaničku i s dítětem? Intervenční a akutní kardiologie 2013; 12 (1): 34–41.

26. Charlot M, Grove EL, Hansen PR et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690. doi: 10.1136/bmj.d2690.

27. Mosorjakova D, Paluch Z, Alusik S. Aspirin resistance. Bratislava Medical Journal. Bratislavske Lekarske Listy 2007; 108 (1): 7–13.

28. Mackenzie IS, Coughtrie MW, MacDonald TM et al. Antiplatelet drug interactions. J Intern Med 2010; 268 (6): 516–529. doi: 10.1111/j.1365-2796.2010.02299.x.

29. Haastrup PF, Gronlykke T, Jarbol DE. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol 2015; 116 (3): 212–215. doi: 10.1111/bcpt.12362.

30. Patrick J, Dillaha L, Armas D et al. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med 2015; 127 (6): 573–580. doi: 10.1080/00325481.2015.1050341.

31. Bhatt DL, Grosser T, Dong JF et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2017; 69 (6): 603–612. doi: 10.1016/j.jacc.2016.11.050.

32. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011; 112 (2): 292–318. doi: 10.1213/ANE.0b013e318203f38d.

33. Elliott WJ. Drug interactions and drugs that affect blood pressure. J Clin Hypertens (Greenwich) 2006; 8 (10): 731–737. doi: 10.1111/j.1524-6175. 2006.05939.x.

34. Medscape Interaction checker. Elektronická databáze. Dostupné na: https: //reference.medscape.com/drug-interactionchecker.

35. Lukáš M. Polymorbidní senior z pohledu gastroenterologa. Medicína pro praxi 2013; 10 (9–10): 300–303.

36. Rychlíčková J. Consequences of hypoacidity induced by proton pump inhibitors – a practical approach. Klin Onkol 2018; 31 (6): 409–413. doi: 10.14735/amko2018409.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account